FDA previews 2019 plans to address opioid epidemic

Feb 27, 2019 - 03:12 PM
FDA-opioid-plans

Food and Drug Administration Commissioner Scott Gottlieb, M.D., yesterday the agency’s 2019 agenda to address the opioid epidemic. Among other actions, the agency is considering using its authority under the Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018 to mandate short-duration packaging for outpatient dispensing of certain solid, oral dosage forms of immediate-release opioid analgesics to treat acute pain, and require manufacturers to develop technologies such as mail-back pouches to dispose of unused opioid medications. FDA also plans to announce changes to strengthen the Risk Evaluation and Mitigation Strategy for transmucosal immediate-release fentanyl medicines, and issue updated guidance to promote the development of non-opioid drugs to treat pain.

Related News Articles

Headline
FDA approves first-in-class non-opioid painkiller 
The Food and Drug Administration Jan. 30 announced it approved Journavx (suzetrigine) oral tablets, a first-in-class non-opioid drug, to treat moderate to…
Headline
AHA podcast: Englewood Health's Strategies to Combat Rising Opioid Use in Post-Pandemic America
In this conversation, Vinnidhy Dave, D.O., hospice specialist and director of palliative medicine at Englewood Health Physician Network, and Lauren Savage,…
Headline
AHA podcast: Thinking Outside the Box to Reduce Behavioral Health Stigma and Disparities 
In this conversation, Matthew Hoag, director of integrated behavioral health at Denver Health, shares how the organization is innovating through integration to…
Headline
'Take Back Day' Oct. 28 to dispose safely of prescription drugs
Oct. 28 is National Prescription Drug Take Back Day, an opportunity for the public to safely dispose of unwanted or expired tablets, capsules, patches and…
Headline
Agencies target unapproved pharmaceutical products from India
Federal agencies last month stopped over 500 unapproved pharmaceutical products and medical devices, including opioid and other controlled substances, from…
Headline
AHA sends SUPPORT Act reauthorization recommendations to House committee  
As the House Energy and Commerce Committee works to reauthorize key programs within the Substance Use-Disorder Prevention that Promotes Opioid Recovery and…